Cancers | Highly Cited Papers in 2023 in the Section “Cancer Drug Development”
As all of the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our most highly cited papers published in 2023 in the Section “Cancer Drug Development”, which are listed below:
1. “Nature’s Green Potential: Anticancer Properties of Plants of the Euphorbiaceae Family”
by Víctor Jiménez-González, Tomasz Kowalczyk, Janusz Piekarski, Janusz Szemraj, Patricia Rijo and Przemysław Sitarek
Cancers 2024, 16(1), 114; https://doi.org/10.3390/cancers16010114
Available online: https://www.mdpi.com/2072-6694/16/1/114
2. “Role of c-Src in Carcinogenesis and Drug Resistance”
by Lukmon Raji, Angelina Tetteh and A. R. M. Ruhul Amin
Cancers 2024, 16(1), 32; https://doi.org/10.3390/cancers16010032
Available online: https://www.mdpi.com/2072-6694/16/1/32
3. “Modulation of Notch Signaling by Small-Molecular Compounds and Its Potential in Anticancer Studies”
by Arkadiusz Czerwonka, Joanna Kałafut and Matthias Nees
Cancers 2023, 15(18), 4563; https://doi.org/10.3390/cancers15184563
Available online: https://www.mdpi.com/2072-6694/15/18/4563
4. “MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential”
by Junjiang Fu, Saber Imani, Mei-Yi Wu and Ray-Chang Wu
Cancers 2023, 15(19), 4723; https://doi.org/10.3390/cancers15194723
Available online: https://www.mdpi.com/2072-6694/15/19/4723
5. “SIRT1 Promotes Cisplatin Resistance in Bladder Cancer via Beclin1 Deacetylation-Mediated Autophagy”
by Yan Sun, Xudong Liu, Hang Tong, Hubin Yin, Tinghao Li, Junlong Zhu, Junrui Chen, Linfeng Wu, Xiaoyu Zhang, Xin Gou et al.
Cancers 2024, 16(1), 125; https://doi.org/10.3390/cancers16010125
Available online: https://www.mdpi.com/2072-6694/16/1/125
6. “Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies”
by Jibran Ahmed, Biswajit Das, Sarah Shin and Alice Chen
Cancers 2023, 15(24), 5841; https://doi.org/10.3390/cancers15245841
Available online: https://www.mdpi.com/2072-6694/15/24/5841
7. “Mutation Status and Glucose Availability Affect the Response to Mitochondria-Targeted Quercetin Derivative in Breast Cancer Cells”
by Paweł Przybylski, Anna Lewińska, Iwona Rzeszutek, Dominika Błoniarz, Aleksandra Moskal, Gabriela Betlej, Anna Deręgowska, Martyna Cybularczyk-Cecotka, Tomasz Szmatoła, Grzegorz Litwinienko et al.
Cancers 2023, 15(23), 5614; https://doi.org/10.3390/cancers15235614
Available online: https://www.mdpi.com/2072-6694/15/23/5614
8. “Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT”
by Hwan Lee, Sarit T. Kipnis, Remy Niman, Sophia R. O’Brien, Jennifer R. Eads, Bryson W. Katona and Daniel A. Pryma
Cancers 2024, 16(1), 200; https://doi.org/10.3390/cancers16010200
Available online: https://www.mdpi.com/2072-6694/16/1/200
9. “STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs”
by Mircea T. Chiriac, Zsuzsanna Hracsko, Christoph Becker and Markus F. Neurath
Cancers 2023, 15(22), 5423; https://doi.org/10.3390/cancers15225423
Available online: https://www.mdpi.com/2072-6694/15/22/5423
10. “First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors”
by Anna R. Schreiber, Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim et al.
Cancers 2024, 16(1), 91; https://doi.org/10.3390/cancers16010091
Available online: https://www.mdpi.com/2072-6694/16/1/91
You are invited to view and submit relevant papers to the journal Cancers.
Cancers Editorial Office